AR and posterior cortical atrophy: Over the past decade, enzalutamide, a second‐generation AR antagonist, and abiraterone, a CYP17A1 inhibitor, have proven effective against mCRPC and rapidly become standard therapies for advanced‐stage PCa [4, 5].